In this episode, Thomas Fuchs, Chief AI Officer at Eli Lilly, shares his journey from early machine learning research to spearheading transformative AI initiatives across the pharmaceutical value chain. Lilly is running over a thousand AI projects—from drug discovery and development to manufacturing and commercial operations—leveraging innovations like language models for chatbots, computer vision for quality control, and biomarker development.
Thomas emphasizes trust, transparency, and collaboration as critical to AI adoption, supported by AI certification programs for all Lilly technology employees, as well as AI education resources being made available for everyone at Lilly. He also highlights the company’s unique “lab-in-the-loop” setups that generate synthetic data to accelerate innovation.
Thomas shares real-world successes, including AI-assisted drug discovery and intelligent chatbots, and how AI is building confidence across the organization. With robust data infrastructure and scalable strategies for synthesizing large datasets, Lilly is driving rapid innovation. Thomas predicts faster drug design, broader access to medicines, and continuous education as defining trends for AI in healthcare. Take a listen.
Dr. Albert Chan, Chief Digital Officer of Sutter Health, shares with us on how digital is about opportunities to enhance the experience for patients
In this podcast, Jason Considine, Chief Business Development Officer at Experian Health, discusses the critical role of data in digital healthcare systems. He explains...
In this episode, Paula Turicchi, Chief Strategy Officer, Parkland Community Health Plan (PCHP), talks about how the organization went from a completely outsourced service...
